These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3896099)

  • 1. The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects.
    Hommer DW; Pickar D; Crawley JN; Weingartner H; Paul SM
    Ann N Y Acad Sci; 1985; 448():542-52. PubMed ID: 3896099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of ceruletide in schizophrenia.
    Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM
    Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceruletide resembles antipsychotics in rats and schizophrenic patients. Preliminary report.
    van Ree JM; Verhoeven WM; Brouwer GJ; de Wied D
    Neuropsychobiology; 1984; 12(1):4-8. PubMed ID: 6151145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceruletide for schizophrenia: a double-blind study.
    Mattes JA; Hom W; Rochford JM; Orlosky M
    Biol Psychiatry; 1985 May; 20(5):533-8. PubMed ID: 2859054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results.
    Albus M; von Gellhorn K; Münch U; Naber D; Ackenheil M
    Psychiatry Res; 1986 Sep; 19(1):1-7. PubMed ID: 3538106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin and ceruletide in schizophrenic patients.
    Verhoeven WM; Westenberg HG; van Ree JM
    Acta Psychiatr Scand; 1986 Apr; 73(4):372-82. PubMed ID: 3524119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ceruletide on clinical symptoms and EEGS in schizophrenia.
    Mizuki Y; Ushijima I; Habu K; Nakamura K; Yamada M
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):511-22. PubMed ID: 3406428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia.
    Lotstra F; Verbanck PM; Gilles C; Mendlewicz J; Vanderhaeghen JJ
    Ann N Y Acad Sci; 1985; 448():507-17. PubMed ID: 3896098
    [No Abstract]   [Full Text] [Related]  

  • 9. A high-dose, double-blind study of ceruletide in the treatment of schizophrenia.
    Mattes JA; Hom W; Rochford JM
    Am J Psychiatry; 1985 Dec; 142(12):1482-4. PubMed ID: 3907376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecystokinin peptides, dopamine and schizophrenia--a review.
    Nair NP; Lal S; Bloom DM
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):515-24. PubMed ID: 2868491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia.
    Moroji T; Watanabe N; Aoki N; Itoh S
    Int Pharmacopsychiatry; 1982; 17(4):255-73. PubMed ID: 7185770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric disease.
    Chase TN; Barone P; Bruno G; Cohen SL; Juncos J; Knight M; Ruggeri S; Steardo L; Tamminga CA
    Ann N Y Acad Sci; 1985; 448():553-61. PubMed ID: 3896100
    [No Abstract]   [Full Text] [Related]  

  • 13. Antipsychotic effects of ceruletide in chronic schizophrenia. An appraisal of the long-term, intermittent medication of ceruletide in chronic schizophrenia.
    Moroji T; Itoh K; Itoh K
    Ann N Y Acad Sci; 1985; 448():518-34. PubMed ID: 3927809
    [No Abstract]   [Full Text] [Related]  

  • 14. Is cholecystokinin therapeutic in chronic schizophrenia?
    Boza RA; Rotondo DJ
    J Clin Psychiatry; 1985 Nov; 46(11):485-6. PubMed ID: 3902807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceruletide improves event-related potential indicators of cognitive processing in young but not in elderly humans.
    Dodt C; Sarnighausen HE; Pietrowsky R; Fehm HL; Born J
    J Clin Psychopharmacol; 1996 Dec; 16(6):440-5. PubMed ID: 8959469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: effects on tremors induced by oxotremorine, harmine and ibogaine. A comparison with prolyl-leucylglycine amide (MIF), anti-Parkinsonian drugs and clonazepam.
    Zetler G
    Neuropharmacology; 1983 Jun; 22(6):757-66. PubMed ID: 6310434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin-induced effects on selective attention depend on level of activation.
    Pietrowsky R; Rudolf S; Mölle M; Fehm HL; Born J
    Neuropsychobiology; 1997; 36(2):87-95. PubMed ID: 9267858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
    Feifel D; Reza T; Robeck S
    Neuropsychopharmacology; 1999 Feb; 20(2):141-9. PubMed ID: 9885794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons.
    Schreiber H; Stolz-Born G; Pietrowsky R; Kornhuber HH; Fehm HL; Born J
    Biol Psychiatry; 1995 May; 37(10):702-12. PubMed ID: 7640325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effect of CCK-8 and ceruletide on glutamate-induced rises in intracellular free calcium concentrations in rat neuron cultures.
    Shinohara S; Katsuura G; Eigyo M; Shintaku H; Ibii N; Matsushita A
    Brain Res; 1992 Aug; 588(2):223-8. PubMed ID: 1356589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.